Mesoblast scores FDA committee's backing for cell therapy despite some early worries

Cell and gene therapy makers have to contend with a laundry list of concerns on the road to approval, including a complicated manufacturing process and often, some regulatory pushback. Facing what was expected to be an FDA firing line over its cell therapy, Mesoblast is instead looking at a clear path to market.